Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer

被引:23
作者
Jakubowska, Katarzyna [1 ]
Kisielewski, Wojciech [2 ]
Kanczuga-Koda, Luiza [1 ]
Koda, Mariusz [3 ]
Famulski, Waldemar [1 ,2 ]
机构
[1] Med Univ Bialystok, Comprehens Canc Ctr, Dept Pathomorphol, Bialystok, Poland
[2] Med Univ Bialystok, Dept Med Pathomorphol, Bialystok, Poland
[3] Med Univ Bialystok, Dept Gen Pathomorphol, Bialystok, Poland
关键词
inflammatory cell infiltration; colorectal cancer; TSP; immune response; OVARIAN-CANCER; STAGE-II; PROGNOSIS; METASTASES; MICROENVIRONMENT; LYMPHOCYTES; RECURRENCE; GROWTH;
D O I
10.3892/ol.2017.6639
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The anticancer immune defense mechanism involves humoral and cellular responses. The main effector mechanisms of antitumor responses involve the following: the activity of cytotoxic T cells; the activation of macrophages and neutrophils; the activity of cytokines secreted by T cells; and natural killer cell activity. Selected cell populations are responsible for the stimulation or suppression of the immune system against tumor cells. Therefore, the aim of the present study was to evaluate the location, extent and composition of the cellular inflammatory infiltration of tumors in patients with colorectal cancer (CRC). In addition, the correlation between cellular inflammatory infiltration, and anatomoclinical and histopathological features of patients was evaluated. The study involved 160 patients diagnosed with primary operable CRC. The local inflammatory infiltrate was assessed in the invasive front and center of the tumor using light microscopy with hematoxylin and eosin (H&E) staining, according to the Klintrup-Makinen criteria, tumor stroma percentage, and Glasgow microenvironment score. The inflammatory infiltrate in the invasive front of the tumor was correlated with gender (P=0.018), the invasion of blood vessels (P=0.020) and lymph vessels (P=0.038), the presence of tumor-infiltrating lymphocytes in the invasive front (P=0.033) and center (P<0.001) of the tumor, fibrosis (P<0.001), and the degree of desmoplasmic stroma (P=0.004). In contrast, inflammatory infiltration in the center of the tumor was associated with the tumor node metastasis stage (P=0.012), Dukes' stage (P=0.009), primary tumor stage (P=0.036), lymph node status (P=0.005), number of lymph nodes (P=0.006), invasion of lymph node pouches (P=0.021), size of lymph node metastasis (P=0.025) and the degree of desmoplasmic stroma (P=0.002). The low-group, who demonstrated an absent or weak inflammatory cell infiltrate in the invasive front of the tumor, had a statistically significant shorter disease-free survival (DFS) time (P=0.004). Inflammatory cell infiltrate in the invasive front was identified as an independent predictive factor in CRC (P=0.041). In conclusion, the degree of inflammatory cell infiltration in the invasive front of the primary tumor significantly affects various variables that determine disease progression and DFS rates of patients with CRC. Furthermore, the routine histopathological assessment of this parameter in tissue stained with H&E may have potential prognostic value.
引用
收藏
页码:3869 / 3877
页数:9
相关论文
共 30 条
  • [1] [Anonymous], 2014, PROBL HIG EPIDEMIOL
  • [2] Conti John, 2011, Cancers (Basel), V3, P2160, DOI 10.3390/cancers3022160
  • [3] The Desmoplastic Reaction Surrounding Hepatic Colorectal Adenocarcinoma Metastases Aids Tumor Growth and Survival via αv Integrin Ligation
    Conti, John A.
    Kendall, Timothy J.
    Bateman, Adrian
    Armstrong, Thomas A.
    Papa-Adams, Andrew
    Xu, Qian
    Packham, Graham
    Primrose, John N.
    Benyon, R. Christopher
    Iredale, John P.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (20) : 6405 - 6413
  • [4] Role of desmoplasia in recurrence of stage II colorectal cancer within five years after surgery and therapeutic implication
    Crispino, Pietro
    De Toma, Giorgio
    Ciardi, Antonio
    Bella, Antonino
    Rivera, Margherita
    Cavallaro, Giuseppe
    Polistena, Andrea
    Fornari, Francesca
    Unim, Hans
    Pica, Roberta
    Cassieri, Claudio
    Mingazzini, Pietro Luigi
    Paoluzi, Paolo
    [J]. CANCER INVESTIGATION, 2008, 26 (04) : 419 - 425
  • [5] Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum
    Cui, Guanglin
    Goll, Rasmus
    Olsen, Trine
    Steigen, Sonja Eriksson
    Husebekk, Anne
    Vonen, Barthold
    Florholmen, Jon
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (07) : 985 - 995
  • [6] Stromal myofibroblasts are drivers of invasive cancer growth
    De Wever, Olivier
    Demetter, Pieter
    Mareel, Marc
    Bracke, Marc
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (10) : 2229 - 2238
  • [7] Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy
    Dvorak, Harold F.
    [J]. CANCER JOURNAL, 2015, 21 (04) : 237 - 243
  • [8] Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    Galon, Jerom
    Costes, Anne
    Sanchez-Cabo, Fatima
    Kirilovsky, Amos
    Mlecnik, Bernhard
    Lagorce-Pages, Christine
    Tosolini, Marie
    Camus, Matthieu
    Berger, Anne
    Wind, Philippe
    Zinzindohoue, Franck
    Bruneval, Patrick
    Cugnenc, Paul-Henri
    Trajanoski, Zlatko
    Fridman, Wolf-Herman
    Pages, Franck
    [J]. SCIENCE, 2006, 313 (5795) : 1960 - 1964
  • [9] The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial
    Huijbers, A.
    Tollenaar, R. A. E. M.
    v Pelt, G. W.
    Zeestraten, E. C. M.
    Dutton, S.
    McConkey, C. C.
    Domingo, E.
    Smit, V. T. H. B. M.
    Midgley, R.
    Warren, B. F.
    Johnstone, E. C.
    Kerr, D. J.
    Mesker, W. E.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 179 - 185
  • [10] Inflammation and prognosis in colorectal cancer
    Klintrup, K
    Mäkinen, JM
    Kauppila, S
    Väre, PO
    Melkko, J
    Tuominen, H
    Tuppurainen, K
    Mäkelä, J
    Karttunen, TJ
    Mäkinen, MJ
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (17) : 2645 - 2654